Literature DB >> 10638566

Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease.

K E McColl1, A Dickson, A El-Nujumi, E El-Omar, A Kelman.   

Abstract

OBJECTIVES: Eradication of Helicobacter pylori (H. pylori) infection markedly reduces the recurrence of duodenal and gastric ulcers. However, there is little information regarding its efficacy in resolving dyspeptic symptoms in ulcer patients. The primary aim of this study was to assess the effect of eradicating H. pylori infection on dyspeptic symptoms in ulcer patients. The secondary aim was to identify predictors of symptomatic response to H. pylori eradication.
METHODS: A total of 97 dyspeptic patients with active duodenal and/or gastric ulceration associated with H. pylori infection and unrelated to NSAID use had the severity and character of their dyspeptic symptoms measured before and again 1-3 yr after H. pylori eradication therapy.
RESULTS: Pretreatment, the median dyspepsia score was 12 (4-16). Posttreatment, 55% of those eradicated of H. pylori had resolution of dyspepsia (score <2) compared with 18% of those not eradicated of the infection (95% CI for difference, 11-62%). Of the ulcer patients 31% had symptoms and/or endoscopic evidence of coexisting gastroesophageal reflux disease (GERD) at initial presentation and this influenced the symptomatic response to eradication of H. pylori. Of the 22 patients with heartburn or acid reflux as the predominant presenting symptom, but no endoscopic esophagitis, only 27% experienced resolution of dyspepsia after H. pylori eradication, compared with 68% of the 59 without those as predominant symptoms (95% CI for difference, 18-63%). Only one of the five patients with coexisting endoscopic esophagitis at initial presentation experienced resolution of dyspepsia after H. pylori eradication. Symptomatic benefit was unrelated to time lapsed since the infection was eradicated. Only three of 50 subjects developed de novo GERD symptoms after eradication of H. pylori, whereas 21 of 36 subjects experienced resolution of GERD symptoms after eradication of the infection.
CONCLUSIONS: A substantial proportion of ulcer patients have symptoms and/or signs of coexisting GERD at initial presentation and this reduces the symptomatic benefit from H. pylori eradication. However, we have found no evidence that eradicating H. pylori induces de novo GERD symptoms in ulcer patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10638566     DOI: 10.1111/j.1572-0241.2000.01706.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  16 in total

1.  Eradication of Helicobacter pylori and use of antisecretory drugs: population based cohort study.

Authors:  Annmarie Lassen; Jesper Hallas; Ove B Schaffalitzky de Muckadell
Journal:  BMJ       Date:  2003-09-13

Review 2.  Barrett esophagus: an update.

Authors:  Rami J Badreddine; Kenneth K Wang
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-06-01       Impact factor: 46.802

Review 3.  Consequences of Helicobacter pylori infection in children.

Authors:  Lucia Pacifico; Caterina Anania; John F Osborn; Flavia Ferraro; Claudio Chiesa
Journal:  World J Gastroenterol       Date:  2010-11-07       Impact factor: 5.742

4.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

5.  Cost-effectiveness of six strategies for Helicobacter pylori diagnosis and management in uninvestigated dyspepsia assuming a high resource intensity practice pattern.

Authors:  Kyland P Holmes; John C Fang; Brian R Jackson
Journal:  BMC Health Serv Res       Date:  2010-12-21       Impact factor: 2.655

6.  Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial.

Authors:  Naoki Chiba; Sander J O Veldhuyzen Van Zanten; Paul Sinclair; Ralph A Ferguson; Sergio Escobedo; Eileen Grace
Journal:  BMJ       Date:  2002-04-27

7.  Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial.

Authors:  E J Kuipers; G F Nelis; E C Klinkenberg-Knol; P Snel; D Goldfain; J J Kolkman; H P M Festen; J Dent; P Zeitoun; N Havu; M Lamm; A Walan
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

Review 8.  Epidemiology of gastric cancer.

Authors:  Katherine D Crew; Alfred I Neugut
Journal:  World J Gastroenterol       Date:  2006-01-21       Impact factor: 5.742

9.  The effect of Helicobacter pylori infection and eradication in patients with gastro-oesophageal reflux disease: A parallel-group, double-blind, placebo-controlled multicentre study.

Authors:  Werner Schwizer; Dieter Menne; Kurt Schütze; Michael Vieth; Reiner Goergens; Peter Malfertheiner; Andreas Leodolter; Michael Fried; Mark R Fox
Journal:  United European Gastroenterol J       Date:  2013-08       Impact factor: 4.623

Review 10.  A rational approach to uninvestigated dyspepsia in primary care: review of the literature.

Authors:  N L A Arents; J C Thijs; J H Kleibeuker
Journal:  Postgrad Med J       Date:  2002-12       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.